Drug · CHEMBL986
RETINOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. RETINOL. Drugs and targets, record CHEMBL986. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL986
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases27
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 27Source Open Targets
See all 27 diseasesTrials65
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02906566 | Retinol on Human Skin Aging in East Asian Descent | Phase 4 | 110 | 2019-04-16 | retinol | Its name | ClinicalTrials.gov |
| NCT02649192 | Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children | Phase 2 | 87 | 2019-09-25 | vitamin A | Its name | ClinicalTrials.gov |
| NCT03112863 | Comparison of the Cosmetic Effects of Bakuchiol and Retinol | Early phase 1 | 44 | 2021-11-02 | retinol | Its name | ClinicalTrials.gov |
| NCT01283464 | Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles | Phase 2 | 24 | 2013-08-20 | retinol | Its name | ClinicalTrials.gov |
| NCT03870529 | High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer | Early phase 1 | 20 | 2024-01-09 | vitamin A | Its name | ClinicalTrials.gov |
| NCT00222547 | Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6 | Phase 4 | 720,000 | vitamin A | Its name | ClinicalTrials.gov | |
| NCT01138449 | Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial) | 44,984 | vitamin A | Its name | ClinicalTrials.gov | ||
| NCT00198718 | Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates | Phase 2 | 28,220 | vitamin A | Its name | ClinicalTrials.gov | |
| NCT00114868 | Vitamin A Supplementation in Newborns Study | Phase 3 | 14,035 | vitamin A | Its name | ClinicalTrials.gov | |
| NCT00168636 | Different Doses of Vitamin A Supplementation and Male and Female Morbidity and Mortality | Phase 4 | 11,000 | vitamin a | Its name | ClinicalTrials.gov |
1 to 10 of 65
See all 65 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Older Group Ages 55-75 vs Young Group Ages 18-25: deaths from any cause | 0 of 24 | 0 of 10 | 34 | NCT02906566 | Trial comparisons |
| Older Group Ages 55-75 vs Young Group Ages 18-25: serious adverse events | 0 of 24 | 0 of 10 | 34 | NCT02906566 | Trial comparisons |
| Retinol vs Tretinoin: serious adverse events | 1 of 12 | 2 of 12 | 24 | NCT01283464 | Trial comparisons |
| Vitamin A Compound vs Therapeutic Conventional Surgery: deaths from any cause | 0 of 11 | 0 of 9 | 20 | NCT03870529 | Trial comparisons |
| Vitamin A Compound vs Therapeutic Conventional Surgery: serious adverse events | 0 of 11 | 0 of 9 | 20 | NCT03870529 | Trial comparisons |
Papers from its trials77
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL986
GET https://conductscience.org/api/drugs/v1/CHEMBL986/diseases?page=2